NUTEX HEALTH INC (NUTX) Stock Fundamental Analysis
USA - NASDAQ:NUTX - US67079U3068 - Common Stock
109.03 USD
+14.2 (+14.97%)
Overall NUTX gets a fundamental rating of 6 out of 10. We evaluated NUTX against 101 industry peers in the Health Care Providers & Services industry. NUTX has an average financial health and profitability rating. NUTX is growing strongly while it is still valued neutral. This is a good combination! This makes NUTX very considerable for growth investing!
1. Profitability
1.1 Basic Checks
In the past year NUTX was profitable.
NUTX had a positive operating cash flow in the past year.
In the past 5 years NUTX reported 4 times negative net income.
In multiple years NUTX reported negative operating cash flow during the last 5 years.
1.2 Ratios
With an excellent Return On Assets value of 8.82%, NUTX belongs to the best of the industry, outperforming 93.07% of the companies in the same industry.
The Return On Equity of NUTX (34.08%) is better than 94.06% of its industry peers.
With an excellent Return On Invested Capital value of 30.54%, NUTX belongs to the best of the industry, outperforming 99.01% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.82% | ||
| ROE | 34.08% | ||
| ROIC | 30.54% |
ROA(3y)-33.97%
ROA(5y)-688.28%
ROE(3y)-160.63%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NUTX has a better Profit Margin (10.76%) than 93.07% of its industry peers.
The Operating Margin of NUTX (33.39%) is better than 99.01% of its industry peers.
Looking at the Gross Margin, with a value of 48.77%, NUTX is in the better half of the industry, outperforming 74.26% of the companies in the same industry.
In the last couple of years the Gross Margin of NUTX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.39% | ||
| PM (TTM) | 10.76% | ||
| GM | 48.77% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y22.83%
GM growth 5Y0.83%
2. Health
2.1 Basic Checks
NUTX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for NUTX has been reduced compared to 1 year ago.
NUTX has more shares outstanding than it did 5 years ago.
NUTX has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.01 indicates that NUTX is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a Altman-Z score value of 2.01, NUTX perfoms like the industry average, outperforming 47.52% of the companies in the same industry.
NUTX has a debt to FCF ratio of 4.45. This is a neutral value as NUTX would need 4.45 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 4.45, NUTX is in the better half of the industry, outperforming 73.27% of the companies in the same industry.
A Debt/Equity ratio of 1.46 is on the high side and indicates that NUTX has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.46, NUTX is doing worse than 68.32% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.46 | ||
| Debt/FCF | 4.45 | ||
| Altman-Z | 2.01 |
ROIC/WACC4.32
WACC7.07%
2.3 Liquidity
A Current Ratio of 2.27 indicates that NUTX has no problem at all paying its short term obligations.
NUTX has a better Current ratio (2.27) than 79.21% of its industry peers.
A Quick Ratio of 2.26 indicates that NUTX has no problem at all paying its short term obligations.
NUTX has a Quick ratio of 2.26. This is in the better half of the industry: NUTX outperforms 79.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.27 | ||
| Quick Ratio | 2.26 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 430.28% over the past year.
Looking at the last year, NUTX shows a very strong growth in Revenue. The Revenue has grown by 141.25%.
Measured over the past years, NUTX shows a very strong growth in Revenue. The Revenue has been growing by 222.96% on average per year.
EPS 1Y (TTM)430.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%526.67%
Revenue 1Y (TTM)141.25%
Revenue growth 3Y194.48%
Revenue growth 5Y222.96%
Sales Q2Q%213.98%
3.2 Future
Based on estimates for the next years, NUTX will show a very negative growth in Earnings Per Share. The EPS will decrease by -28.46% on average per year.
Based on estimates for the next years, NUTX will show a very strong growth in Revenue. The Revenue will grow by 72.84% on average per year.
EPS Next Y-60.63%
EPS Next 2Y-28.46%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year186.75%
Revenue Next 2Y72.84%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 9.17, the valuation of NUTX can be described as very reasonable.
Compared to the rest of the industry, the Price/Earnings ratio of NUTX indicates a rather cheap valuation: NUTX is cheaper than 98.02% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.42, NUTX is valued rather cheaply.
A Price/Forward Earnings ratio of 24.40 indicates a rather expensive valuation of NUTX.
NUTX's Price/Forward Earnings ratio is in line with the industry average.
NUTX's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.94.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.17 | ||
| Fwd PE | 24.4 |
4.2 Price Multiples
NUTX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. NUTX is cheaper than 99.01% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of NUTX indicates a rather cheap valuation: NUTX is cheaper than 90.10% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.73 | ||
| EV/EBITDA | 3.26 |
4.3 Compensation for Growth
The decent profitability rating of NUTX may justify a higher PE ratio.
A cheap valuation may be justified as NUTX's earnings are expected to decrease with -28.46% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-28.46%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for NUTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:NUTX (10/20/2025, 11:49:32 AM)
109.03
+14.2 (+14.97%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners32.21%
Inst Owner Change2.3%
Ins Owners3.03%
Ins Owner Change0%
Market Cap606.21M
Analysts82.22
Price Target246.5 (126.08%)
Short Float %28.86%
Short Ratio4.74
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.25
Dividend Growth(5Y)N/A
DP19.83%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4474.63%
Min EPS beat(2)9.6%
Max EPS beat(2)8939.67%
EPS beat(4)3
Avg EPS beat(4)2105.75%
Min EPS beat(4)-602.61%
Max EPS beat(4)8939.67%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)143.87%
Min Revenue beat(2)76.42%
Max Revenue beat(2)211.33%
Revenue beat(4)4
Avg Revenue beat(4)75.65%
Min Revenue beat(4)5.5%
Max Revenue beat(4)211.33%
Revenue beat(8)5
Avg Revenue beat(8)36.33%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)24.78%
EPS NQ rev (1m)-81.07%
EPS NQ rev (3m)-81.07%
EPS NY rev (1m)-56.63%
EPS NY rev (3m)-56.63%
Revenue NQ rev (1m)15.22%
Revenue NQ rev (3m)18.88%
Revenue NY rev (1m)11.15%
Revenue NY rev (3m)11.54%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.17 | ||
| Fwd PE | 24.4 | ||
| P/S | 0.97 | ||
| P/FCF | 8.73 | ||
| P/OCF | 8.53 | ||
| P/B | 3.08 | ||
| P/tB | 3.61 | ||
| EV/EBITDA | 3.26 |
EPS(TTM)11.89
EY10.91%
EPS(NY)4.47
Fwd EY4.1%
FCF(TTM)12.49
FCFY11.45%
OCF(TTM)12.78
OCFY11.72%
SpS112.28
BVpS35.45
TBVpS30.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.82% | ||
| ROE | 34.08% | ||
| ROCE | 35.61% | ||
| ROIC | 30.54% | ||
| ROICexc | 35.64% | ||
| ROICexgc | 37.81% | ||
| OM | 33.39% | ||
| PM (TTM) | 10.76% | ||
| GM | 48.77% | ||
| FCFM | 11.12% |
ROA(3y)-33.97%
ROA(5y)-688.28%
ROE(3y)-160.63%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y22.83%
GM growth 5Y0.83%
F-Score8
Asset Turnover0.82
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.46 | ||
| Debt/FCF | 4.45 | ||
| Debt/EBITDA | 1.26 | ||
| Cap/Depr | 8.22% | ||
| Cap/Sales | 0.26% | ||
| Interest Coverage | 59.03 | ||
| Cash Conversion | 31.12% | ||
| Profit Quality | 103.36% | ||
| Current Ratio | 2.27 | ||
| Quick Ratio | 2.26 | ||
| Altman-Z | 2.01 |
F-Score8
WACC7.07%
ROIC/WACC4.32
Cap/Depr(3y)59.19%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.66%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)430.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%526.67%
EPS Next Y-60.63%
EPS Next 2Y-28.46%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)141.25%
Revenue growth 3Y194.48%
Revenue growth 5Y222.96%
Sales Q2Q%213.98%
Revenue Next Year186.75%
Revenue Next 2Y72.84%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y4652.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year951.75%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y98.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y31.51%
OCF growth 3YN/A
OCF growth 5YN/A